Background Molecular imaging is increasingly used to guide treatment decisions and
planning in prostate cancer. We aimed to evaluate the role of 18 F-fluciclovine-PET/CT in …

Purpose We explored the influence of FACBC (fluciclovine) PET/CT on the decision to offer
radiotherapy and radiotherapy treatment field recommendations in postprostatectomy …

Summary Background National Comprehensive Cancer Network guidelines consider 18 F-
fluciclovine PET-CT for prostate cancer biochemical recurrence localisation after radical …

Purpose Early and accurate localization of lesions in patients with biochemical recurrence
(BCR) of prostate cancer may guide salvage therapy decisions. The present study, 18 F …

Purpose: The prospective, multicenter LOCATE (18F Fluciclovine [FACBC] PET/CT in
Patients with Rising PSA after Initial Prostate Cancer Treatment) trial assessed the impact of …

Prostate cancer–specific positron emission tomography (pcPET) has been shown to detect
sites of disease recurrence at serum prostate-specific antigen (PSA) levels that are lower …

Background The high positivity rate of prostate-specific membrane antigen (PSMA) PET in
the setting of biochemical failure (BCF), even when conventional imaging is negative, is …

Purpose To investigate the clinical value of 18 F-fluorocholine PET/CT (CH-PET/CT) in
treatment decisions in patients with recurrent prostate cancer (rPCA). Methods The study …

CONTEXT: The role of positron emission tomography (PET) and PET/computed tomography
(PET/CT) in prostate cancer (PCa) imaging is still debated, although guidelines for their use …

Background and purpose The present study evaluates the incidence of 11 C-choline
PET/CT positive findings in patients with recurrent prostate cancer referred for salvage …